LeukoSTAT launched for Veterinary Critical Care

LeukoSTAT Supplement Focuses on the Critical Care Environment By admin | June 4, 2010 April 01, 2010 – IMULAN BioTherapeutics’ new product leukoSTAT, is the first veterinary nutritional product containing the Immune Selective Anti-Inflammatory Derivatives (ImSAID ). This new technology uses naturally occurring amino acid complexes which evolved to regulate leukocytes, the source of all inflammatory processes. These specific amino acid sequences in leukoSTAT have been shown in numerous published studies to attenuate the over activation of the immune system, the underlying cause of all acute and chronic inflammatory conditions. IMULAN intends to evaluate leukoSTAT in a variety of settings to better understand its broad applications in veterinary medicine. IMULAN is now focusing on critical care applications for leukoSTAT, an environment which often has limited options to support patients. The ImSAIDs have been previously evaluated in a variety of in vivo critical care models, including sepsis (e.g. SIRS) and inflammation of the pancreas, lungs, intestines, nervous system, and joints. leukoSTAT comes in highly palatable, small, chewable tablets so that the animal can easily ingest the amino acid complex and immediately begin the process of rebalancing the immune system. IMULAN holds the veterinary patent rights to the ImSAIDs technology platform and will be identifying partners that want to use this technology for nutraceutical use. Imulan develops immune regulating, naturally-occurring substance for veterinary medicine. Imulan’s primary focus is to combine peptide pharmacology with immunology to manage inflammatory, infectious and immune mediated diseases in companion and production animals. Please visit www.IMULAN.com to learn more. ImSAIDs and leukoSTAT are trademarks of IMULAN BioTherapeutics, LLC

IMULAN launches LeukoSTAT

IMULAN Launches LeukoSTAT™; ImSAIDS® – Based TechnologyBy admin | November 29, 2009

(November 12, 2009) – Imulan BioTherapeutics, LLC (IMULAN) announced the release of LeukoSTAT™; a nutritional product containing a newly recognized class of naturally occurring amino acid complexes referred to as ImSAIDs (Immune Selective Anti-Inflammatory Derivatives). Originally discovered as important components of saliva, ImSAIDS have been shown to target leukocytes, thereby going right to the source of inflammation regardless of the cause, making it a useful product for the veterinarian. ImSAIDs have demonstrated positive effects in models of pancreatitis, sepsis, asthma, anaphylaxis, allergic reactions and spinal trauma.

Dr. Craig Woods, CEO of IMULAN, stated, “We are seeing science move away from traditional drugs which focus on blocking enzymes such as cyclo-oxygenase, towards totally natural technologies as exemplified by the ImSAIDS. Researchers can now develop products which modify the cells that make the enzymes, essentially going right to the source of the problem. This becomes a much more powerful and comprehensive tool with broad applications.”

Imulan develops immune regulating, naturally-occurring substance for veterinary medicine. Imulan’s primary focus is to combine peptide pharmacology with immunology to manage inflammatory, infectious and immune mediated diseases in companion and production animals.

Visit www.IMULAN.com or www.LeukoSTAT.com for more information.